Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Kooth PLC (LSE:KOO): What Is Driving Investor Attention on London’s AIM and Main Market on 3 November 2026?

The immediate investment discussion centres on digital mental health service contracts and user engagement. This theme is relevant to Kooth PLC because it influences how investors assess futureEarningsquality,Capitalneeds and the durability of its commercial proposition. A topic attracting attention does not by itself establish …

Ankur Sharma | 03 November 2026

CRISM Therapeutics Corporation (LSE:CRTX): What Is Driving Investor Attention on London’s AIM and Main Market on 3 November 2026?

The immediate investment discussion centres on therapeutics development and commercial milestones. This theme is relevant to CRISM Therapeutics Corporation because it influences how investors assess futureEarningsquality,Capitalneeds and the durability of its commercial proposition. A topic attracting attention does not by itself establish a share-price …

Ankur Sharma | 03 November 2026

Eden Biosolutions PLC (LSE:EDEN): What Is Driving Investor Attention on London’s AIM and Main Market on 3 November 2026?

The immediate investment discussion centres on life-sciences commercial development and customer demand. This theme is relevant to Eden Biosolutions PLC because it influences how investors assess futureEarningsquality,Capitalneeds and the durability of its commercial proposition. A topic attracting attention does not by itself establish a …

Ankur Sharma | 03 November 2026

EKF Diagnostics Holdings plc (LSE:EKF): What Is Driving Investor Attention on London’s AIM and Main Market on 3 November 2026?

The immediate investment discussion centres on diagnostic manufacturing demand and operational efficiency. This theme is relevant to EKF Diagnostics Holdings plc because it influences how investors assess futureEarningsquality,Capitalneeds and the durability of its commercial proposition. A topic attracting attention does not by itself establish …

Ankur Sharma | 03 November 2026

Why Does NIOX Group's (LSE:NIOX) Second Half Hinge on NIOX PRO Within the FTSE AIM UK 50?

For the six months to 30 June 2026, revenue fell 5% to £24.0m from £25.2m, according to the results. Clinical revenue, from sales of devices and tests to healthcare providers, rose 3% to £20.6m.Clinical Trialsrevenue, generated mainly from pharmaceutical companies using the devices in …

Ankur Sharma | 03 November 2026

Which Parts of EKF Diagnostics (LSE:EKF) Must Deliver in the Second Half for the FTSE AIM UK 50 Group to Meet Forecasts?

The board said its expectations for the 2026 financial year were unchanged, and that it expected revenue and adjusted EBITDA growth in line with market expectations. The company cited consensus forecasts of £54.6m of revenue and £13.6m of adjusted EBITDA. On our arithmetic, meeting …

Ankur Sharma | 03 November 2026

How Is H.B. Fuller Financing Its Offer for Advanced Medical Solutions (LSE:AMS) Within the FTSE AIM UK 50?

The development most relevant to deliverability in recent weeks has come from the bidder's side. On 8 October 2026, H.B. Fuller said it had priced US$850m of senior unsecured notes due 2034, carrying a coupon of 7.625% and issued at 100% of principal, with …

Ankur Sharma | 03 November 2026

What Is Still Unknown About the Cyber Incident at Craneware (LSE:CRW) as the FTSE AIM UK 50 Firm Heads to Its AGM?

According to the July announcement, the company said its incident response plan had been activated, the board had appointed external cyber security and forensic specialists, and the incident had been contained. External specialists reportedly confirmed no residual indicators of compromise, and the company said …

Ankur Sharma | 03 November 2026

HUTCHMED (LSE:HCM) reaches review stage in Europe and Japan for ORPATHYS plus TAGRISSO in lung cancer

• Japan's Ministry of Health, Labour and Welfare accepts a New Drug Application for the same lung cancer combination.

Ankur Sharma | 03 November 2026

£2.7m Huntington's disease Phase 3 win adds to IXICO (LSE:IXI) order book momentum

• It is the company's second Phase 3 Huntington's disease award in the past 12 months.

Ankur Sharma | 03 November 2026
Support

Hi! How can we help you today?

Loading…